411 - Application of a SARS-CoV-2-specific serologic assay for translational research and surveillance

The ePoster content is available to users who are logged in.<br><br>Please log in and then come back here to use this button.

Presenting Author(s)

Amy C. Sherman

Instructor
Brigham and Women's Hospital
Brookline, Massachusetts
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Co-Author(s)

TS

Teresa C. Smith

Graduate Student
Rollins School of Public Health, Emory University
Atlanta, Georgia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
DE

Daniel Espinoza

Dr.
Emory University
Atlanta, GA
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
YZ

Yerun Zhu

Dr.
Emory University
Atlanta, GA
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Jessica Howard-Anderson

Infectious Diseases Fellow
Division of Infectious Diseases, Dept. of Medicine, Emory University School of Medicine
Atlanta, Georgia
Disclosure: Antibacterial Resistance Leadership Group (ARLG) (Other Financial or Material Support, The ARLG fellowship provides salary support for ID fellowship and mentored research training)
KT

Kaitlin R. Taibl

Graduate Student
Rollins School of Public Health, Emory University
Atlanta, Georgia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Jessica K. Fairley

Associate Professor
Emory University, Division of Infectious Diseases
Atlanta, Georgia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
HW

Henry M. Wu

Associate Professor
Emory University, Division of Infectious Diseases
Atlanta, Georgia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
SE

Sri Edupuganti

Associate Professor
The Hope Clinic of Emory University
Atlanta, Georgia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Nadine Rouphael

Professor of Medicine- Director of the Hope Clinic
Emory University School of Medicine
Atlanta, Georgia
Disclosure: Lilly (Grant/Research Support)Merck (Grant/Research Support)Pfizer (Grant/Research Support)Quidel (Grant/Research Support)Sanofi Pasteur (Grant/Research Support)
Alfonso J. Rodriguez-Morales

Dr
Fundacion Universitaria Autonoma de las Americas Pereira CO
Pereira, Risaralda, Colombia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
JC

Jaime Cardona Ospina

Director, Facultad de Medicina
Fundación Universitaria Autónoma de las Américas
Medellin, Risaralda, Colombia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
JS

Juan Carlos Sepúlveda Arias

Professor
Universidad Tecnológica de Pereira
Pereira, Risaralda, Colombia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Scott Fridkin

Professor
Georgia Emerging Infections Program, Decatur, GA; Emory University School of Medicine, Atlanta, GA
Atlanta, Georgia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MC

Matthew H. Collins

Assistant Professor
Emory University
Atlanta, Georgia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Background: Sensitive and specific SARS-CoV-2 antibody diagnostics are urgently needed to estimate the seroprevalence of SARS-CoV-2 infection in both the general population and special risk groups. Moreover, validated serologic assays are critical to understanding immunity to SARS-CoV-2 infection over time and identifying correlates of protection.

Methods: An enzyme-linked immunosorbent assay (ELISA) protocol to detect antibodies (IgG) that bind the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein was validated and ROC curve analysis performed by testing a large panel of pre-pandemic sera (n=162) and convalescent sera from RT-PCR-confirmed COVID-19 cases (n=60). We then applied this test in two cohorts: 1) Healthcare personnel (HCP) that were enrolled in a longitudinal surveillance cohort just after peak local transmission and 2) Mildly ill patients being tested for SARS-CoV-2 infection by RT-PCR from NP swabs in an ambulatory testing clinic.Demographics of mildly symptomatic patients tested for SARS-CoV-2 with RT-PCR

Results: ROC curve analysis yielded an AUC of 0.9953, with a sensitivity and specificity at 91.67% and 99.38% at the optimal OD normalization threshold of 0.20. In 240 HCP surveilled at enrollment, 5.83% had positive IgG results. Of 19 symptomatic patients who presented to the ambulatory clinic, 5/19 had a positive PCR. In convalescence (13-74 days post symptom onset), 3 of those 5 were positive for IgG.Validation of the SARS-CoV-2 RBD ELISA

ROC Curve Analysis

Conclusion: We demonstrated high sensitivity and specificity of the SARS-CoV-2 RBD ELISA. This simple assay is an efficient way to track seroconversion and duration of antibody responses to SARS-CoV-2 for different populations, particularly since RBD-binding antibodies have been shown to correlate with neutralization activity and may be useful to determine protective immunity following natural infection or vaccination. Ongoing work will assess variation in magnitude, character and duration of antibody responses in key populations and seek to maximize deployability of large-scale SARS-CoV-2 serology.